Antiatherosclerotic Activities of Raphionacme brownii (Apocynaceae) Elliot-Scott on Rats

NGOUNBE RILENGAR Léon^1, , Hal Souakar AMBERA¹, Kakesse MAGUIRGUE² and Brahim Boy OTCHOM¹

¹University of N'Djamena, Doctoral School of Sciences-Techniques-Environment, Doctoral Training in Biology and Human Health, Research Laboratory, Diagnostics and Scientific Expertise, Toxicology and Pharmacology Unit, Chad

²University of Sarh, Faculty of Science and Technology, Department of Life and Earth Sciences, Biology Laboratory, Toxicology and Pharmacology Unit, Chad

Cite this paper:
NGOUNBE RILENGAR Léon, Hal Souakar AMBERA, Kakesse MAGUIRGUE and Brahim Boy OTCHOM. Antiatherosclerotic Activities of Raphionacme brownii (Apocynaceae) Elliot-Scott on Rats. American Journal of Biomedical Research. 2025; 13(2):20-28. doi: 10.12691/ajbr-13-2-1

Abstract

Our study consisted of evaluating the antiatherosclerotic activity of Raphionacme brownii tubers. The antiatherosclerotic activities were evaluated on rats, subdivided into two phases including the induction of hypercholesterolemia for 30 days and the treatment of hypercholesterolemia for 15 days. The evaluation of the antiatherosclerotic activity revealed a significant decrease in TC to 44.28% in females and 47.98% in males; TG to 34.48% in females and 26.66% in males; LDL to 45.16% in females and 41.30% in males and conversely an increase in HDL to 14.58% in females and 20.75% in males. The atherogenic index showed a better activity of the effect of Raphionacme brownii tubers on atherosclerosis. The richness in bioactive compounds could justify the traditional use of Raphionacme brownii as a hypolipidemic agent treating cardiovascular diseases.

Keywords:
Raphionacme brownii secondary metabolites and atherosclerosis

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	World Health Organization, Cardiovascular Diseases, June 11, 2021.
[2]	Mbewu A, Mbanya JC. In Jamison DT, Feachem RG, Makgoba MW, Bos ER, Baingana FK et al., (2006). Disease and Mortality in Sub-Saharan Africa (2nd edition). Washington (DC). World Bank.
[3]	Tiahou G.; Deret K.; World A.; Agniwo; Camara-Cisse M.; Djohan Y.; Djessou P.; Sess D. (2010): J. sci. pharm. biol., Vol.11, n°2 -, pp. 60-65 © EDUCI 2010.
[4]	WHO, (2015). Global Status Report on Noncommunicable Diseases, 2014. "Achieving the nine global targets: a shared responsibility."p67.
[5]	Ferrieres J. (2008). Prevalence of different dyslipidemias in France, Cardiology Department B, Rangueil University Hospital, Toulouse.
[6]	Charline D, (2020). Dyslipidemia, metabolic diseases. Health on the Net, https://www.health-on-the-net.com/ diseases/ metabolism/ dyslipidemia.
[7]	Naibé DT, D Nahodidje, L Allawaye, MH Langtar. (2016). Hospital morbidity and mortality of cardiovascular diseases in the cardiology department at the national reference general hospital of N'djamena/Chad.
[8]	Oumar Mahamat-Azaki, Abdel-madjid Zakaria Zakaria, Adam Ahamat Ali, Yaya kichiné Mahamat, Yakpelba Rinta Jarius, Hassan Khamiss et al., (2023). Prevalence of dyslipidemia in the biochemistry laboratory of the Reference National Teaching Hospital of N'Djamena, Chad.
[9]	WHO., (2008). WHO Strategy on Traditional Medicine. World Health Organization; Geneva; 65p.
[10]	WHO, (2013). WHO Strategy on Traditional Medicine for 2014-2023, WHO publications, 20 Avenue Appia, 1211 Geneva 27 (Switzerland), 65p, ISBN 978 92 42506099.
[11]	Johnson Oluwaseun Odukoya, Julianah Olayemi Odukoya, Edwin Mpho Mmutlane, and Derek Tantoh Ndinteh. (2022). An ethnopharmacological study of medicinal plants used for the treatment of cardiovascular diseases and their associated risk factors in sub-Saharan Africa.
[12]	Ghizlane Hajjaj. (2017). Phytochemical screening, toxicological study and pharmacological valorization of matricaria chamomilla l. and ormenis mixta l. (asteraceae). Doctoral Thesis No.: 07/16 CSVS.
[13]	Ntchapda Fidèle, Djedouboum Abakar, Blaise Kom, Paulin Nana, Christian Bonabe, Maguirgue Kakesse, Emmanuel Talla. (2014). Diuretic Activity of the Aqueous Extract Leaves of Ficus glumosa Del. (Moraceae) in Rats.The Scientific World Journal.
[14]	Bonnefont-Rousselot D. (2016). Lipid balance. Biology Leaflets/No. 330 - MAY 2016.
[15]	French Agency for the Safety of Health Products (AFSSAPS) (2005). Therapeutic management of dyslipidemic patients.
[16]	Iliassou Halidou, Zourkaleini. (2023). Correlation between lipid consumption and atherogenicity indices in the elderly. Http: //dspace1.univ-tlemcen.dz/handle/112/20779.
[17]	Simon Bissonnette. (2012). The role of apoB-lipoproteins on fat clearance in human subcutaneous white adipose tissue. Master's thesis. University of Montreal. 117p.
[18]	Mir Hakima. (2016). Effect of a freeze-dried extract of lime (Citrus latifolia) peel combined with purified sardine protein on the lipid profile and redox status in HC-rendered Wistar rats. Doctoral thesis in Biological Sciences. University of Oran 1. P94-104.
[19]	WHO (World Health Organization), (2023). Total fat intake for the prevention of excessive weight gain in adults and children: summary of the WHO guideline. Geneva. License: CC BY-NC-SA 3.0 IGO.
[20]	Jean-Michel LECERF. (2008). Lipid intake and weight gain, Quantitative aspects – A debate. OCL VOL. 15 N° 1.
[21]	FOPH (2007). Fats in our diet. Recommendations of the Federal Office of Public Health. http:// www.bag.admin.ch/ themen/ ernaehrung/00211/03131/index.html?lang=fr.
[22]	Vianna Costil, Jean-Christophe Létard, Yann Guérineau, Anne-Sophie Jégo, Jean-Marc Canard, Patrick Faure, Franck Devulder et al., (2010). Dietary advice to prevent cardiovascular risks and lipid disorders (cholesterol, triglycerides). CREGG, ALN editions, ISBN: 978-2-35833-052-7.
[23]	Richard W. James. (2008). What therapeutic approaches to hypo-HDL-cholesterolemia? Swiss Medical Review – www.revmed.ch; 4: 632-5.
[24]	Richard Mbundu Ilunga, Céline Helbing, Lucie Fare, Tinh-hai Collet. (2018). Management of obesity-related dyslipidemia: a diet-centered approach. Rev Med Suisse 2018; 14: 627-32.
[25]	Peter Gesund. (2022). Can cholesterol cause weight gain? In Health Updated December 27, 2022lammarion. 26 p.
[26]	Kahn R, Buse J, Ferannini E, Stern M, (2005). American Diabetes Association and European Association for the Study of Diabetes. The metabolic syndrome: Time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes Care. 28(9): 2289-2304.
[27]	Borén J, Williams KJ. (2016).The central role of arterial retention of cholesterol-rich apolipoprotein-Bcontaining lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. Curr Opin Lipidol; 27:473-83.
[28]	Manel AKD, (2015). Study of the effect of Portulaca oleracea extract on obesity in Wistar rats. 108p. http:dspace.univ-eloued.dz/handle/123456789/135.
[29]	Rezgani I., Mizouri R., Sebai I., Temessek A., Ben Mani F. (2018). Atherogenicity index in the Tunisian diabetic population. Annale d'Endocrinologie, Volume 79, Issue 4, September 2018, page 491.
[30]	Segbenou SJN, (2022). Correlation between blood sugar and atherogenicity index in subjects received in cardiology at Saint Jean Hospital in Cotonou. 51p. http: biblionumeric.epac-uac.org:8080/jspui/handle/12346789/5503.
[31]	Abbes Mohamed Abdelhaq. (2017). Study of the impact of body weight on high blood pressure, Case of hypertensive patients in Tiaret. Doctoral thesis in Sciences. Djilali Liables University. P6.
[32]	Stone NJ, Robinson J, Lichtenstein AH, Bairey Mertz CN, et al. (2013). ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Traffic 2014; 129 (Suppl 2): S1-45.
[33]	Pauline Sarazin. (2014). Hypercholesterolemia and its management. Doctoral thesis in pharmaceutical sciences. ffdumas-01062332ff.
[34]	French: Haute Autorité de Santé (HAS). (2010). Efficacy and effectiveness of lipid-lowering drugs. An analysis focused on statins. Summary. Saint-Denis La Plaine: HAS. http://www.has-sante.fr/portail/upload/docs/.
[35]	French National Authority for Health (HAS). (2016). Pure hypercholesterolemia and mixed hyperlipidemia: management, Framework note. Biology leaflets/No. 333. Website www.has-sante.fr, Evaluation & recommendation section.
[36]	Sybil Charrière. (2024). How to treat hypertriglyceridemia. Medical Training Press, Volume 5, Issue 2, page 132-139.
[37]	Esterbauer H., Ramos P. (1995). Chemistry and pathophysiology of oxidation of LDL. Rev. Physiol. Biochem. Pharmacol., 127, 31-64.
[38]	Bok S.-H., et al. (1999). Plasma and hepatic cholesterol and hepatic activities of 3-hydroxy-3-methyl-glutaryl-CoA reductase and acylCoA: cholesterol transferase are lower in rats fed citrus peel extract or mixture of citrus bioflavonoids. J. Nutr., 129, 1182-1185.
[39]	Vinson JA, et al. (1998). A citrus extract plus ascorbic acid decreases lipids, lipid peroxides lipoprotein oxidative susceptibility, and atherosclerosis in hypercholesterolemic hamster. J. Agric. Food Chem., 46, 1453-1459.
[40]	American Heart Association (AHA). (2009). Stable cardiovascular disease: Raising HDL should complement lowering LDL, judging by a surrogate-endpoint study. The 82nd Scientific Sessions of the American Heart Association. Orlando, Florida.
[41]	Sébastien Tanaka. (2019). Functional and structural evaluation of plasma HDL during inflammatory conditions. Doctoral thesis in Science from the University of Reunion. P52-54.